Type I IFNs Incapable of Inducing Remission in Ulcerative Colitis

Type I IFNs Incapable of Inducing Remission in Ulcerative Colitis
In a recent review study entitled “Type I interferons for induction of remission in ulcerative colitis”, the authors revised clinical studies and concluded that type I interferon therapy, successfully used in several chronic inflammatory diseases, does not induce ulcerative colitis remission in patients with active disease. The study was published in the Cochrane Database of Systematic Reviews. Ulcerative colitis (UC) is one of the main types of inflammatory bowel disease (IBD), together with Crohn's disease, and is characterized by chronic inflammation particularly of the colon and small intestine. Type I interferons (IFNs) are a group of cytokines that regulate the activity of the immune system and have been successfully employed to treat several chronic inflammatory conditions. Here, authors investigated whether type I IFN treatment in patients with active UC induces disease remission. To this end, they performed a systematic revision of literature on the efficacy and safety of type I IFN therapy for induction of UC remission published in several databases, including MEDLINE, EMBASE, CENTRAL, the Cochrane IBD/FBD group specialized register, and ClinicalTrials.gov. Their analysis focused on randomized controlled trials for
Subscribe or to access all post and page content.